Neonatal congenital microvillus atrophy

N. Pecache, Sanjay Patole, Ronald Hagan, D. Hill, Adrian Charles, John Papadimitriou

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Congenital microvillous atrophy (CMVA) is the leading cause of neonatal secretory diarrhoea with onset either in the first 72 hours of life ( early onset) or at 6 - 8 weeks after birth ( late onset). To date over 30 cases have been reported worldwide. The prognosis for this life threatening condition continues to be poor. Therapeutic agents like somatostatin and epidermal growth factor are either ineffective or of marginal benefit. Overall five year survival after small bowel transplantation is currently similar to50%. The following brief review is aimed towards helping neonatologists/ perinatologists in the early diagnosis, and management of CMVA and in counselling the parents appropriately.
Original languageEnglish
Pages (from-to)80-83
JournalPostgraduate Medical Journal
Volume80
Issue number940
DOIs
Publication statusPublished - 2004

Fingerprint

Atrophy
Somatostatin
Epidermal Growth Factor
Counseling
Early Diagnosis
Diarrhea
Transplantation
Parents
Parturition
Survival
Microvillus inclusion disease
Therapeutics
Neonatologists

Cite this

Pecache, N. ; Patole, Sanjay ; Hagan, Ronald ; Hill, D. ; Charles, Adrian ; Papadimitriou, John. / Neonatal congenital microvillus atrophy. In: Postgraduate Medical Journal. 2004 ; Vol. 80, No. 940. pp. 80-83.
@article{33a3536a5a3041dabb053d870dfce2db,
title = "Neonatal congenital microvillus atrophy",
abstract = "Congenital microvillous atrophy (CMVA) is the leading cause of neonatal secretory diarrhoea with onset either in the first 72 hours of life ( early onset) or at 6 - 8 weeks after birth ( late onset). To date over 30 cases have been reported worldwide. The prognosis for this life threatening condition continues to be poor. Therapeutic agents like somatostatin and epidermal growth factor are either ineffective or of marginal benefit. Overall five year survival after small bowel transplantation is currently similar to50{\%}. The following brief review is aimed towards helping neonatologists/ perinatologists in the early diagnosis, and management of CMVA and in counselling the parents appropriately.",
author = "N. Pecache and Sanjay Patole and Ronald Hagan and D. Hill and Adrian Charles and John Papadimitriou",
year = "2004",
doi = "10.1136/pmj.2003.007930",
language = "English",
volume = "80",
pages = "80--83",
journal = "Postgraduate Medical Journal",
issn = "0032-5473",
publisher = "BMJ Publishing Group",
number = "940",

}

Neonatal congenital microvillus atrophy. / Pecache, N.; Patole, Sanjay; Hagan, Ronald; Hill, D.; Charles, Adrian; Papadimitriou, John.

In: Postgraduate Medical Journal, Vol. 80, No. 940, 2004, p. 80-83.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Neonatal congenital microvillus atrophy

AU - Pecache, N.

AU - Patole, Sanjay

AU - Hagan, Ronald

AU - Hill, D.

AU - Charles, Adrian

AU - Papadimitriou, John

PY - 2004

Y1 - 2004

N2 - Congenital microvillous atrophy (CMVA) is the leading cause of neonatal secretory diarrhoea with onset either in the first 72 hours of life ( early onset) or at 6 - 8 weeks after birth ( late onset). To date over 30 cases have been reported worldwide. The prognosis for this life threatening condition continues to be poor. Therapeutic agents like somatostatin and epidermal growth factor are either ineffective or of marginal benefit. Overall five year survival after small bowel transplantation is currently similar to50%. The following brief review is aimed towards helping neonatologists/ perinatologists in the early diagnosis, and management of CMVA and in counselling the parents appropriately.

AB - Congenital microvillous atrophy (CMVA) is the leading cause of neonatal secretory diarrhoea with onset either in the first 72 hours of life ( early onset) or at 6 - 8 weeks after birth ( late onset). To date over 30 cases have been reported worldwide. The prognosis for this life threatening condition continues to be poor. Therapeutic agents like somatostatin and epidermal growth factor are either ineffective or of marginal benefit. Overall five year survival after small bowel transplantation is currently similar to50%. The following brief review is aimed towards helping neonatologists/ perinatologists in the early diagnosis, and management of CMVA and in counselling the parents appropriately.

U2 - 10.1136/pmj.2003.007930

DO - 10.1136/pmj.2003.007930

M3 - Review article

VL - 80

SP - 80

EP - 83

JO - Postgraduate Medical Journal

JF - Postgraduate Medical Journal

SN - 0032-5473

IS - 940

ER -